NMT Capital

NMT Capital operates a dual sourcing engine. As a principal investor it evaluates deals for its own funds; simultaneously it acts as a paid consultant to global investment banks seeking to source and evaluate private medical companies. This advisory work gives NMT early visibility into companies considering a sale or capital raise, creating a proprietary pipeline not available to firms relying solely on standard GP networks.

NMT Capital invests across the full spectrum, from seed and early-stage venture capital through growth and late-stage expansion to buyouts. This multi-stage approach allows the firm to back companies at inception via its venture allocation and supply follow-on capital via its growth and buyout vehicles as those companies mature.

The firm describes its advisory services as a distinct consulting line assisting investment banks in sourcing and evaluating private medical companies, but it does not publicly detail how it prevents information asymmetry between its advisory clients and its own fund portfolios. The same principals averaging more than 20 years of experience oversee both activities.

NMT Capital does not publicly disclose assets under management, cumulative deployment, or fund sizes. Its web presence is limited to a single-page description of strategy and geography, and no public SEC filing or press release has been identified that reports a fund size or AUM figure.